Retirement Systems of Alabama lessened its stake in Illumina, Inc. (NASDAQ:ILMN – Free Report) by 79.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 31,666 shares of the life sciences company’s stock after selling 124,821 shares during the period. Retirement Systems of Alabama’s holdings in Illumina were worth $8,666,000 at the end of the most recent reporting period.
Other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. bought a new position in Illumina during the second quarter valued at about $3,374,423,000. WCM Investment Management LLC lifted its position in shares of Illumina by 45.5% in the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after acquiring an additional 1,851,848 shares during the period. Primecap Management Co. CA bought a new stake in shares of Illumina in the 2nd quarter worth approximately $617,981,000. Ninety One UK Ltd lifted its position in shares of Illumina by 37,920.0% in the 3rd quarter. Ninety One UK Ltd now owns 1,359,974 shares of the life sciences company’s stock worth $372,198,000 after acquiring an additional 1,356,397 shares during the period. Finally, Jupiter Topco LLC acquired a new stake in shares of Illumina during the 2nd quarter worth approximately $358,652,000. 89.42% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of analysts have recently issued reports on ILMN shares. Citigroup boosted their price objective on Illumina from $113.00 to $210.00 and gave the company a “sell” rating in a research report on Monday, November 2nd. Piper Sandler raised their target price on Illumina from $225.00 to $305.00 and gave the stock an “overweight” rating in a research report on Monday, September 28th. Evercore reiterated an “underperform” rating on shares of Illumina in a research note on Friday, October 30th. Stephens lowered shares of Illumina from an “overweight” rating to an “equal weight” rating and set a $275.00 price target on the stock. in a report on Friday, October 23rd. Finally, TD Cowen increased their price objective on shares of Illumina from $210.00 to $270.00 and gave the company a “hold” rating in a research note on Tuesday, October 13th. Ten analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $244.24.
View Our Latest Stock Report on Illumina
Insiders Place Their Bets
In other Illumina news, Director Keith Meister sold 98,833 shares of the stock in a transaction on Wednesday, November 11th. The stock was sold at an average price of $216.87, for a total transaction of $21,433,912.71. Following the completion of the transaction, the director directly owned 208,826 shares in the company, valued at $45,288,094.62. This represents a 32.12% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Scott Ericksen sold 267 shares of Illumina stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $217.76, for a total value of $58,141.92. Following the transaction, the chief accounting officer directly owned 14,029 shares of the company’s stock, valued at approximately $3,054,955.04. The trade was a 1.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,881,899 shares of company stock worth $415,905,954 over the last quarter. Company insiders own 2.90% of the company’s stock.
Illumina Price Performance
NASDAQ ILMN opened at $207.01 on Monday. Illumina, Inc. has a 1-year low of $112.65 and a 1-year high of $309.35. The company has a market capitalization of $31.30 billion, a price-to-earnings ratio of 35.63, a PEG ratio of 2.81 and a beta of 1.46. The stock’s 50 day moving average is $249.02 and its two-hundred day moving average is $179.64. The company has a current ratio of 2.63, a quick ratio of 2.05 and a debt-to-equity ratio of 0.57.
Illumina (NASDAQ:ILMN – Get Free Report) last issued its earnings results on Thursday, October 29th. The life sciences company reported $1.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.36 by $0.26. The business had revenue of $1.17 billion during the quarter, compared to analysts’ expectations of $1.15 billion. Illumina had a return on equity of 28.38% and a net margin of 19.72%. Illumina’s quarterly revenue was up 4.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.34 EPS. Equities analysts forecast that Illumina, Inc. will post 5.43 earnings per share for the current fiscal year.
More Illumina News
These are some of the ILMN news items that stood out recently:
- Neutral Sentiment: Analyst views remain divided, with ratings ranging from Sell to Buy. The reported consensus target is $244.24, while estimates reflect competing expectations for clinical demand and AI-related opportunities versus execution and valuation risks. Analyst Debate on Illumina’s Growth Outlook
- Neutral Sentiment: Chief Accounting Officer Scott Ericksen sold 267 shares under a pre-arranged Rule 10b5-1 plan, a relatively small reduction in his holdings. SEC filing
- Negative Sentiment: Director Keith Meister sold 280,091 shares for approximately $61.1 million across November 9–11, cutting his direct stake substantially. The scale of the sales could concern investors, although he retained a sizable holding. SEC filing
Illumina Company Profile
Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.
Read More
- Five stocks we like better than Illumina
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN – Free Report).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.
